

## Prof. UĞUR COŞKUN

### Personal Information

Email: ugur.coskun@gazi.edu.tr

Web: <https://avesis.gazi.edu.tr/ugur.coskun>

### Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Nivolumab-induced sensory ganglionopathy.**  
Coskun Ö., Sahin H., Yalcin S., Sahin Y. C., Coskun U.  
*Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*, vol.29, no.6, pp.1510-1515, 2023 (SCI-Expanded)
- II. **Lobular breast cancer metastasis to uterus during adjuvant tamoxifen treatment: A case report and review of the literature.**  
Aytekin A., Bilgetekin I., Ciltas A., Ogut B., Coskun U., Benekli M.  
*Journal of cancer research and therapeutics*, vol.14, no.5, pp.1135-1137, 2018 (SCI-Expanded)
- III. **Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer**  
Cinieri S., Chan A., Altundag K., Vandebroek A., Tubiana-Mathieu N., Barnadas A., Dodyk P., Lazzarelli S., Botha M., Rauch D., et al.  
*CLINICAL BREAST CANCER*, vol.17, no.2, pp.91-99, 2017 (SCI-Expanded)
- IV. **Renal cell cancer: overview of the current therapeutic landscape**  
ERMAN M., Benekli M., Basaran M., Bavbek S., Buyukberber S., Coskun U., Demir G., KARABULUT B., Oksuzoglu B., ÖZKAN M., et al.  
*EXPERT REVIEW OF ANTICANCER THERAPY*, vol.16, no.9, pp.955-968, 2016 (SCI-Expanded)
- V. **Factors Influencing Chemotherapy Goal Perception in Newly Diagnosed Cancer Patients**  
GÜMÜŞAY Ö., Cetin B., Benekli M., Gurcan G., İLHAN M. N., Bostankolu B., ÖZET A., ÜNER A., Coskun U., Buyukberber S.  
*JOURNAL OF CANCER EDUCATION*, vol.31, no.2, pp.308-313, 2016 (SCI-Expanded)
- VI. **Crizotinib-induced toxicity in an experimental rat model**  
Gümüşay Ö., Esenagli-Yilmaz G., Üner A., Çetin B., Buyukberber S., Benekli M., İlhan M. N., Coskun U., Gülbahar Ö., Özett A.  
*WIENER KLINISCHE WOCHENSCHRIFT*, vol.128, pp.435-441, 2016 (SCI-Expanded)
- VII. **Comparison of Long-Term Outcomes in Real-World Patients between Resolute Zotarilumus-Eluting and Paclitaxel-Eluting Stents in Small Vessel**  
Kilickesmez K. O., Kocas B., Yildiz A., Coskun U., ERSANLI M. K., Arat A., Gürmen T.  
*Angiology*, vol.67, no.5, pp.490-495, 2016 (SCI-Expanded)
- VIII. **Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab**  
Tonyali O., Coskun U., Yuksel S., İNANÇ M., Bal O., Akman T., Yazilitas D., Ulas A., KÜÇÜKÖNER M., Aksoy A., et al.  
*BREAST*, vol.25, pp.22-26, 2016 (SCI-Expanded)
- IX. **Liver metastases from adenocarcinomas of unknown primary site: management and prognosis in 68 consecutive patients**  
Algın E., ÖZET A., GÜMÜŞAY Ö., Yilmaz G., Buyukberber S., Coskun U., Baykara M., Cetin B., YILDIZ R., Benekli M.  
*WIENER KLINISCHE WOCHENSCHRIFT*, vol.128, pp.42-47, 2016 (SCI-Expanded)
- X. **The impact of immunohistochemical staining with ezrin-carbonic anhydrase IX and neuropilin-2 on**

- prognosis in patients with metastatic renal cell cancer receiving tyrosine kinase inhibitors**  
Cetin B., Gonu I. I., Buyukberber S., Afsar B., Gumasay O., Algın E., TURAN N., ÖZET A., Benekli M., Coskun U.  
TUMOR BIOLOGY, vol.36, no.11, pp.8471-8478, 2015 (SCI-Expanded)
- XI. Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers**  
Baykara M., Benekli M., EKİNCİ Ö., Irkkan S. C., Karaca H., Demirci U., AKINCI M. B., Unal O. U., Dane F., Turkoz F. P., et al.  
JOURNAL OF GASTROINTESTINAL SURGERY, vol.19, no.9, pp.1565-1571, 2015 (SCI-Expanded)
- XII. Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)**  
İÇLİ F., Altundag K., AKBULUT H., PAYDAŞ S., BAŞARAN G., Saip P., GÖKÖZ DOĞU G., Erlap Y., Uslu R., Sevinc A., et al.  
BREAST CANCER, vol.22, no.5, pp.480-485, 2015 (SCI-Expanded)
- XIII. Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma**  
TURAN N., Benekli M., Unal O. U., Unek I. T., Tastekin D., Dane F., Algın E., Ulger S., Eren T., Topcu T. O., et al.  
CHINESE JOURNAL OF CANCER RESEARCH, vol.27, no.4, pp.408-416, 2015 (SCI-Expanded)
- XIV. Cutaneous melanoma in Turkey: analysis of 1157 patients in the Melanoma Turkish Study**  
Abali H., ÇELİK İ., Karaca B., TURNA Z. H., Saglam E. K., Akman T., Oztop I., COŞKUN H. Ş., Turhal N. S., Sezer A., et al.  
JOURNAL OF BUON, vol.20, no.4, pp.1137-1141, 2015 (SCI-Expanded)
- XV. Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites**  
Gumasay O., Benekli M., EKİNCİ Ö., Baykara M., ÖZET A., Coskun U., Demirci U., ÜNER A., DURSUN A., Atak E. Y., et al.  
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.45, no.5, pp.416-421, 2015 (SCI-Expanded)
- XVI. Factors predicting the development of distant metastases in patients with head and neck squamous cell carcinoma: A retrospective study from a single centre**  
Gumasay O., ÖZET A., Buyukberber S., Baykara M., Coskun U., Cetin B., ÜNER A., AYDIL U., Benekli M.  
JOURNAL OF BUON, vol.20, no.2, pp.521-526, 2015 (SCI-Expanded)
- XVII. Functional and Morphological Effects of Systemic Bevacizumab on Cancer Patients' Eyes**  
Yildiz B. K., ÖZDEK Ş., Demirci U., Ceylanoglu K. S., Ozmen M. C., Baykara M., Buyukberber S., Coskun U., Benekli M.  
OPTOMETRY AND VISION SCIENCE, vol.92, no.1, pp.102-106, 2015 (SCI-Expanded)
- XVIII. Association between survival and maximum standardized uptake value of liver metastases detected by 18-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography in patients with adenocarcinoma of unknown primary origin**  
Algın E., ÖZET A., Gumasay O., Cetin B., AKDEMİR Ü. Ö., Benekli M., Coskun U., ÜNER A., Kapucu O., Buyukberber S.  
ANNALS OF NUCLEAR MEDICINE, vol.28, no.9, pp.891-896, 2014 (SCI-Expanded)
- XIX. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology**  
Kaplan M. A., Isikdogan A., Koca D., KÜÇÜKÖNER M., Gumasay O., Yildiz R., Dayan A., DEMİR L., Geredeli C., Kocer M., et al.  
BREAST CANCER, vol.21, no.6, pp.677-683, 2014 (SCI-Expanded)
- XX. Factors predicting recurrence in patients with grade III gliial tumors: Impact of adjuvant temozolomide on recurrence**  
Gumasay O., Cetin B., Ozet A., Demirci U., Buyukberber S., Coskun U., Algın E., ÜNER A., YILDIZ R., Kuri G., et al.  
JOURNAL OF BUON, vol.19, no.4, pp.1035-1040, 2014 (SCI-Expanded)
- XXI. Outcome of 561 non-metastatic triple negative breast cancer patients: Multi-center experience from Turkey**  
Budakoglu B., Altundag K., Aksoy S., Kaplan M. A., Ozdemir N. Y., Berk V., ÖZKAN M., Algın E., Kandemir N., DOĞU G. G., et al.  
JOURNAL OF BUON, vol.19, no.4, pp.872-878, 2014 (SCI-Expanded)
- XXII. Management of brain metastases from non-small cell lung cancer**  
Baykara M., KURT G., Buyukberber S., Demirci U., Ceviker N., Algın E., Coskun U., AYKOL Ş., Emmez H., ÖZET A., et al.  
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.10, no.4, pp.915-921, 2014 (SCI-Expanded)

- XXIII. Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO)**  
Cetin B., Benekli M., Turker I., Koral L., Ulas A., Dane F., Oksuzoglu B., Kaplan M. A., Koca D., Boruban C., et al.  
JOURNAL OF CHEMOTHERAPY, vol.26, no.5, pp.300-305, 2014 (SCI-Expanded)
- XXIV. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer**  
Turan N., Benekli M., Dane F., Unal O. U., Kara H. V., Koca D., Balvan O., Eren T., Tastekin D., Helvaci K., et al.  
THORACIC CANCER, vol.5, no.5, pp.398-404, 2014 (SCI-Expanded)
- XXV. Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma**  
Cetin B., Afsar B., Deger S. M., İŞIK GÖNÜL İ., Gümüşay O., ÖZET A., Benekli M., Coskun U., Buyukberber S.  
INTERNATIONAL UROLOGY AND NEPHROLOGY, vol.46, no.6, pp.1081-1087, 2014 (SCI-Expanded)
- XXVI. Clear Cell Adenocarcinoma of the Uterine Cervix: A Case Report and Review of the Literature**  
Baykara M., Benekli M., ERDEM O. A., Taskiran C., Demirci U., Vargol E., Gunaydin Y., Coskun U., ÖZET A.,  
Buyukberber S.  
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, vol.36, no.2, 2014 (SCI-Expanded)
- XXVII. Docetaxel and Cisplatin in First Line Treatment of Patients with Unknown Primary Cancer: A Multicenter Study of the Anatolian Society of Medical Oncology**  
Demirci U., Coskun U., Karaca H., Dane F., Ozdemir N. Y., Ulas A., Baykara M., Benekli M., ÖZKAN M., Buyukberber S.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.4, pp.1581-1584, 2014 (SCI-Expanded)
- XXVIII. Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology**  
Gümüşay O., Coskun U., Akman T., Ekinci A. S., Kocar M., Erceleb O. B., Yazici O., Kaplan M. A., Berk V., Cetin B., et al.  
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.140, no.1, pp.151-157, 2014 (SCI-Expanded)
- XXIX. Clinical and prognostic importance of XIAP and USP8 in advanced stages of non-small cell lung cancer.**  
Baykara M., Yaman M., Buyukberber S., Tufan G., Demirci U., Benekli M., Coskun U., Ozet A., BAĞRIAÇIK E. Ü.  
Journal of B.U.ON.: official journal of the Balkan Union of Oncology, vol.18, no.4, pp.921-7, 2013 (SCI-Expanded)
- XXX. Prognostic Factors for Recurrence-Free Survival in Patients with HER2-Positive Early-Stage Breast Cancer Treated with Adjuvant Trastuzumab**  
Tonyali O., Coskun U., Sener N., İNANÇ M., Akman T., Ulas A., Yazilitas D., Bal O., KÜÇÜKÖNER M., Ozdemir N. Y., et al.  
ONKOLOGIE, vol.36, no.10, pp.554-558, 2013 (SCI-Expanded)
- XXXI. Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience**  
KEFELİ U., Benekli M., Sevinc A., Yildiz R., Kaplan M. A., Ciltas A., Balakan O., Isikdogan A., Coskun U., Dane F., et al.  
ONCOLOGY LETTERS, vol.6, no.2, pp.605-611, 2013 (SCI-Expanded)
- XXXII. The role of positron emission tomography with 18F-fluorodeoxyglucose in nodal staging of clinical and radiological N-0 head and neck cancers**  
Cetin B., Atasever T., AKDEMİR Ü. Ö., Senturk S., Tufan G., Turan N., Buyukberber S., Coskun U., Benekli M.  
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, vol.270, no.8, pp.2307-2313, 2013 (SCI-Expanded)
- XXXIII. Efficacy and safety of concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced nasopharyngeal cancers**  
Baykara M., Buyukberber S., Ozturk B., Coskun U., Kaplan M. A., Unsal D. K., Dane F., Demirci U., BORA H., Benekli M.  
TUMORI, vol.99, no.4, pp.469-473, 2013 (SCI-Expanded)
- XXXIV. Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer**  
Tonyali O., Benekli M., Berk V., Coskun U., ÖZKAN M., Yildiz R., Ucgul E., Sevinc A., Uncu D., Demirci U., et al.  
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.139, no.6, pp.981-986, 2013 (SCI-Expanded)
- XXXV. Prognostic Factors in Gastrointestinal Stromal Tumors: Multicenter Experience of 333 Cases from Turkey**  
Seker M., Sevinc A., YILDIZ R., Cihan S., Kaplan M. A., Gokdurnali A., Dane F., Yaman E., Karaca H., Colak D., et al.

- HEPATO-GASTROENTEROLOGY, vol.60, no.124, pp.768-775, 2013 (SCI-Expanded)
- XXXVI. Efficacy of Sunitinib in Turkish Patients with Gastrointestinal Stromal Tumors; Retrospective Multicenter Experience**
- KEFELİ U., Buyukberber S., Akyol M., Yildiz R., Kaplan M. A., Ciltas A., Sevinc A., Karaca H., Seker M., Ozdemir N., et al.  
HEPATO-GASTROENTEROLOGY, vol.60, no.124, pp.647-652, 2013 (SCI-Expanded)
- XXXVII. Is the Pretreatment Neutrophil to Lymphocyte Ratio an Important Prognostic Parameter in Patients with Metastatic Renal Cell Carcinoma?**
- Cetin B., Berk V., Kaplan M. A., Afsar B., Tufan G., Ozkan M., Isikdogan A., Benekli M., Coskun U., Buyukberber S.  
CLINICAL GENITOURINARY CANCER, vol.11, no.2, pp.141-148, 2013 (SCI-Expanded)
- XXXVIII. Bevacizumab plus irinotecan in recurrent or progressive malignant glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)**
- Demirci U., Tufan G., Aktas B., Balakan O., ALACACIOĞLU A., Dane F., ENGİN H., Kaplan M. A., Gunaydin Y., Ozdemir N. Y., et al.  
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.139, no.5, pp.829-835, 2013 (SCI-Expanded)
- XXXIX. Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study**
- Akinci M. B., Algin E., Inal A., Odabas H., Berk V., Coskun U., Uyeturk U., Isikdogan A., Aksoy S., Civelek B., et al.  
JOURNAL OF BUON, vol.18, no.2, pp.314-320, 2013 (SCI-Expanded)
- XL. Prognostic factors and clinical outcome of patients with Ewing's sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncology**
- Arpacı E., Yetisigit T., Seker M., Uncu D., ÜYETÜRK Ü., Oksuzoglu B., Demirci U., Coskun U., KÜÇÜKÖNER M., Isikdogan A., et al.  
MEDICAL ONCOLOGY, vol.30, no.1, 2013 (SCI-Expanded)
- XLI. Bevacizumab-containing Chemotherapy is Safe in Patients with Unresectable Metastatic Colorectal Cancer and a Synchronous Asymptomatic Primary Tumor**
- Cetin B., Kaplan M. A., Berk V., Tufan G., Benekli M., Isikdogan A., ÖZKAN M., Coskun U., Buyukberber S.  
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.43, no.1, pp.28-32, 2013 (SCI-Expanded)
- XLII. Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience**
- Cetin B., Benekli M., Dane F., Boruban C., Gumus M., Oksuzoglu B., Kaplan M. A., Tufan G., Sevinc A., Coskun U., et al.  
BREAST CARE, vol.8, no.1, pp.67-70, 2013 (SCI-Expanded)
- XLIII. Efficacy and Safety of Concomitant Chemoradiotherapy with Cisplatin and Docetaxel in Patients with Locally Advanced Squamous Cell Head and Neck Cancers**
- Baykara M., Buyukberber S., Ozturk B., Coskun U., Unsal D. K., Demirci U., Dane F., Kaplan M. A., BORA H., Benekli M.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.4, pp.2557-2561, 2013 (SCI-Expanded)
- XLIV. Lapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience**
- Cetin B., Benekli M., Oksuzoglu B., Koral L., Ulas A., Dane F., Turker I., Kaplan M. A., Koca D., Boruban C., et al.  
ONKOLOGIE, vol.35, no.12, pp.740-745, 2012 (SCI-Expanded)
- XLV. Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer**
- Tonyali O., Coskun U., Sener N., İNANÇ M., Akman T., Oksuzoglu B., Ozdemir N. Y., Yazilitas D., Benekli M., ÜNER A., et al.  
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.138, no.12, pp.2145-2151, 2012 (SCI-Expanded)
- XLVI. Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer**
- Degertekin C. K., Coskun U., TÖRÜNER F. S., Akturk M. Y., Demirci U.  
ENDOCRINE, vol.42, no.3, pp.756-757, 2012 (SCI-Expanded)
- XLVII. Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade gli tumors during temozolamide and radiotherapy.**
- Demirci U., Yaman M., Buyukberber S., Coskun U., Baykara M., Uslu K., Ozet A., Benekli M., BAĞRIAÇIK E. Ü.

- International immunopharmacology, vol.14, no.4, pp.546-9, 2012 (SCI-Expanded)
- XLVIII. Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer**
- YILDIZ R., Benekli M., ÖZKAN M., Alkis N., Berk V., Kaplan M. A., Ciltas A., Karaca H., Durnali A. G., Coskun U., et al.  
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.138, no.11, pp.1845-1852, 2012 (SCI-Expanded)
- XLIX. Paclitaxel plus Doxorubicin Chemotherapy as Second-Line Therapy in Patients with Advanced Urothelial Carcinoma Pretreated with Platinum plus Gemcitabine Chemotherapy**
- Kaya A. O., Coskun U., ÖZKAN M., Sevinc A., Yilmaz A. U., Gumus M., Unal O. U., Ozdemir N. Y., Alici S., Berk V., et al.  
ONKOLOGIE, vol.35, no.10, pp.576-580, 2012 (SCI-Expanded)
- L. Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients**
- Kaya A. O., Gunel N., Benekli M., Akyurek N., Buyukberber S., Tatli H., Coskun U., Yildiz R., Yaman E., Ozturk B.  
JOURNAL OF BUON, vol.17, no.4, pp.663-668, 2012 (SCI-Expanded)
- LI. A previously unreported malignancy of the thyroid**
- Cetin B., Buyukberber S., Senturk S., Uluoglu O., Coskun U., Benekli M.  
MEDICAL ONCOLOGY, vol.29, no.3, pp.1418-1420, 2012 (SCI-Expanded)
- LII. The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens**
- Kaya A. O., Coskun U., Gumus M., Dane F., ÖZKAN M., Isikdogan A., Alkis N., Buyukberber S., Yumuk F., Budakoglu B., et al.  
JOURNAL OF CHEMOTHERAPY, vol.24, no.4, pp.217-220, 2012 (SCI-Expanded)
- LIII. Trabectedin in advanced soft tissue sarcoma: case series**
- Demirci U., Buyukberber S., Yetisigit T., Dizdar O., Benekli M., Alkis N., Coskun U.  
JOURNAL OF BUON, vol.17, no.3, pp.591-592, 2012 (SCI-Expanded)
- LIV. Synchronous Bilateral Breast Cancer in a Patient With Kindler Syndrome**
- Tonyali O., Tufan G., Benekli M., Coskun U., Buyukberber S.  
CLINICAL BREAST CANCER, vol.12, no.2, pp.145-146, 2012 (SCI-Expanded)
- LV. Long term experience in high grade glial tumors with temozolomide**
- Demirci U., Buyukberber S., Coskun U., Akmansu M., Yaman E., Baykara M., Yamac D., Uner A., Benekli M.  
JOURNAL OF BUON, vol.17, no.2, pp.357-362, 2012 (SCI-Expanded)
- LVI. Lymphoproliferative Disorders in Multiple Primary Cancers**
- Demirci U., Ozdemir N., Benekli M., Babacan N. A., Cetin B., Baykara M., Coskun U., Zengin N., Buyukberber S.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.1, pp.383-386, 2012 (SCI-Expanded)
- LVII. Gemcitabine Plus Paclitaxel as Second-line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer**
- Baykara M., Coskun U., Berk V., Ozkan M., Kaplan M. A., Benekli M., Karaca H., Inanc M., Isikdogan A., Sevinc A., et al.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.10, pp.5119-5124, 2012 (SCI-Expanded)
- LVIII. Hepatotoxicity associated with lapatinib in an experimental rat model**
- Demirci U., Buyukberber S., Yilmaz G., KEREM M., Coskun U., ÜNER A., Baykara M., Pasali H., Benekli M.  
EUROPEAN JOURNAL OF CANCER, vol.48, no.2, pp.279-285, 2012 (SCI-Expanded)
- LIX. Clinicopathological Features in Bilateral Breast Cancer**
- Baykara M., Ozturk S. C., Buyukberber S., Helvaci K., Ozdemir N., Alkis N., Berk V., Koca D., Coskun U., Oksuzoglu B., et al.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.9, pp.4571-4575, 2012 (SCI-Expanded)
- LX. Prognostic Factors for Overall Survival in Patients With Metastatic Colorectal Carcinoma Treated With Vascular Endothelial Growth Factor-Targeting Agents**
- Cetin B., Kaplan M. A., Berk V., Ozturk S. C., Benekli M., Isikdogan A., ÖZKAN M., Coskun U., Buyukberber S.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.3, pp.1059-1063, 2012 (SCI-Expanded)
- LXI. Gemcitabine and Cisplatin Combination Chemotherapy in Triple Negative Metastatic Breast Cancer Previously Treated with a Taxane/Anthracycline Chemotherapy; Multicenter Experience**

- Ozkan M., Berk V., Kaplan M. A., Benekli M., Coskun U., Bilici A., Gumus M., Alkis N., Dane F., Ozdemir N. Y., et al.  
NEOPLASMA, vol.59, no.1, pp.38-42, 2012 (SCI-Expanded)
- LXII. **Efficacy and Toxicity of Gemcitabine Plus Docetaxel Combination as a Second Line Therapy for Patients with Advanced Stage Soft Tissue Sarcoma**  
Kaya A. O., Buyukberber S., ÖZKAN M., Alkis N., Sevinc A., Ozdemir N. Y., Alici S., Esbah O., Berk V., Camci C., et al.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.2, pp.463-467, 2012 (SCI-Expanded)
- LXIII. **Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma**  
Baykara M., Akkus M., YILDIZ R., İŞIK GÖNÜL İ., DURSUN A., Coskun U., Benekli M., Sevinc A., Dane F., Buyukberber S.  
INTERNATIONAL IMMUNOPHARMACOLOGY, vol.11, no.12, pp.2227-2231, 2011 (SCI-Expanded)
- LXIV. **Kaposi's sarcoma in patients with ulcerative colitis receiving immunosuppressive drugs: Report of a case**  
Cetin B., Buyukberber S., Yilmaz I. B., YILDIZ R., Coskun U., Benekli M.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.22, no.6, pp.621-625, 2011 (SCI-Expanded)
- LXV. **Assessment of right ventricular functions during cancer chemotherapy.**  
Tanindi A., Demirci U., TAÇOY G., Buyukberber S., Alsancak Y., Coskun U., Yalcin R., Benekli M.  
European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology, vol.12, no.11, pp.834-40, 2011 (SCI-Expanded)
- LXVI. **Sister Mary Joseph's nodule as a rare sign of lymphoma**  
Cetin B., Benekli M., Bulutay P., AKYÜREK N., Cura E., Coskun U., Buyukberber S.  
INTERNATIONAL JOURNAL OF HEMATOLOGY, vol.94, no.2, pp.209-212, 2011 (SCI-Expanded)
- LXVII. **Ischemic colitis after capecitabine plus cisplatin treatment in advanced gastric cancer**  
Cetin B., Buyukberber S., Senturk S., Guzel E., Coskun U., Benekli M.  
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, vol.31, no.4, pp.503-506, 2011 (SCI-Expanded)
- LXVIII. **Metastasis of rectal cancer to soft tissue of the hand: An unusual case**  
Cetin B., Buyukberber S., Yuksel M., Coskun U., YILDIZ R., Benekli M.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.22, no.2, pp.229-230, 2011 (SCI-Expanded)
- LXIX. **Primary adult soft tissue sarcomas: analysis of 294 patients**  
Alkis N., Muallaoglu S., Kocer M., Arslan U. Y., Durnali A. G., Tokluoglu S., Celenkoglu G., Paksoy F., Coskun U.  
MEDICAL ONCOLOGY, vol.28, no.1, pp.391-396, 2011 (SCI-Expanded)
- LXX. **Serum granulocyte colony-stimulating factor levels in gliomas**  
Yildiz R., Coskun U., Buyukberber S., Sancak B., Kaya A. O., Gulbahar Ö., Benekli M.  
JOURNAL OF BUON, vol.16, no.1, pp.138-141, 2011 (SCI-Expanded)
- LXXI. **Intracystic papillary carcinoma of the breast: one of the youngest patient in the literature**  
Baykara M., Coskun U., Demirci U., YILDIZ R., Benekli M., Cakir A., Buyukberber S.  
MEDICAL ONCOLOGY, vol.27, no.4, pp.1427-1428, 2010 (SCI-Expanded)
- LXXII. **Peritumoral Lymphatic Microvessel Density Associated with Tumor Progression and Poor Prognosis in Gastric Carcinoma**  
Coskun U., AKYÜREK N., DURSUN A., Yamac D.  
JOURNAL OF SURGICAL RESEARCH, vol.164, no.1, pp.110-115, 2010 (SCI-Expanded)
- LXXIII. **Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide**  
Yaman E., Buyukberber S., Benekli M., Oner Y., Coskun U., AKMANSU M., Ozturk B., Kaya A. O., Uncu D., YILDIZ R.  
CLINICAL NEUROLOGY AND NEUROSURGERY, vol.112, no.8, pp.662-667, 2010 (SCI-Expanded)
- LXXIV. **The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer**  
YILDIZ R., Benekli M., Buyukberber S., Kaya A. O., Ozturk B., Yaman E., Berk V., Coskun U., Yamac D., Sancak B., et al.  
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.136, no.10, pp.1471-1476, 2010 (SCI-Expanded)
- LXXV. **Parathyroid Adenoma and Chondrosarcoma After Treatment of Pediatric Hodgkin Disease**  
Keskin E. Y., Gursel T., Uluoglu O., Albayrak M., KAYA Z., Coskun U., KOÇAK Ü.  
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, vol.32, no.7, 2010 (SCI-Expanded)
- LXXVI. **Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors**

- Tonyali O., Coskun U., YILDIZ R., KARAKAN T., Demirci U., AKYÜREK N., Benekli M., Buyukberber S.  
MEDICAL ONCOLOGY, vol.27, no.3, pp.768-773, 2010 (SCI-Expanded)
- LXXVII. **Serum M30 levels are associated with survival in advanced gastric carcinoma patients**  
Yaman E., Coskun U., Sancak B., Buyukberber S., Ozturk B., Benekli M.  
INTERNATIONAL IMMUNOPHARMACOLOGY, vol.10, no.7, pp.719-722, 2010 (SCI-Expanded)
- LXXVIII. **Bilateral breast cancer in a survivor of acute lymphoblastic leukemia: a case report**  
Demirci U., Bugdayci F., Cakir A., Gurlek B., İŞIK GÖNÜL İ., Buyukberber S., Benekli M., Coskun U.  
MEDICAL ONCOLOGY, vol.27, no.2, pp.481-483, 2010 (SCI-Expanded)
- LXXIX. **Cisplatin plus docetaxel combination in the first-line treatment of metastatic non-small cell lung cancer**  
Kaya A. O., Buyukberber S., Dane F., Isikdogan A., Ustaalioglu B. O., Coskun U., Yumuk P. F., Dogu G. G., Ozdemir N. Y., Sevinc A., et al.  
TUMORI J, vol.96, no.3, pp.400-404, 2010 (SCI-Expanded)
- LXXX. **Efficacy and toxicity of preoperative chemotherapy with docetaxel and epirubicin in locally advanced invasive breast cancer**  
Kaya A. O., Coskun U., Buyukberber S., Benekli M., Tekin E., Cifter C., Ozturk B., Yildiz R., Yaman E., Uner A., et al.  
JOURNAL OF BUON, vol.15, no.2, pp.248-254, 2010 (SCI-Expanded)
- LXXXI. **Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer**  
Kaya A. O., Buyukberber S., Benekli M., Coskun U., Sevinc A., AKMANSU M., YILDIZ R., Ozturk B., Yaman E., KALENDER M. E., et al.  
MEDICAL ONCOLOGY, vol.27, no.1, pp.152-157, 2010 (SCI-Expanded)
- LXXXII. **Synchronous Bilateral Breast Cancer in an Aged Male Patient**  
Yaman E., Ozturk B., Coskun U., Buyukberber S., Kaya A. O., YILDIZ R., Benekli M.  
ONKOLOGIE, vol.33, no.5, pp.255-258, 2010 (SCI-Expanded)
- LXXXIII. **Coexistence Hodgkin's lymphoma and colonic adenocarcinoma: a case report**  
Demirci U., Buyukberber S., Yilmaz G., Ozturk B., AKYÜREK N., YILDIZ R., Tonyali O., Coskun U., Benekli M.  
MEDICAL ONCOLOGY, vol.27, no.1, pp.62-64, 2010 (SCI-Expanded)
- LXXXIV. **Granulocyte colony stimulating factor (G-CSF) and macrophage colony stimulating factor (M-CSF) as potential tumor markers in non small cell lung cancer diagnosis.**  
Bahar B., Acedil Ayc Iota B., Çoşkun U., Büyükerber S., Benekli M., Yildiz R.  
Asian Pacific journal of cancer prevention : APJCP, vol.11, no.3, pp.709-12, 2010 (SCI-Expanded)
- LXXXV. **Bevacizumab Plus Irinotecan-Based Therapy in Metastatic Colorectal Cancer Patients Previously Treated With Oxaliplatin-Based Regimens**  
YILDIZ R., Buyukberber S., ÜNER A., Yamac D., Coskun U., Kaya A. O., Ozturk B., Yaman E., Benekli M.  
CANCER INVESTIGATION, vol.28, no.1, pp.33-37, 2010 (SCI-Expanded)
- LXXXVI. **Adult hepatic epithelioid haemangioendothelioma presenting with Kasabach-Merrit syndrome: a case report**  
Ozturk B., Coskun U., Yaman E., Cakir A., Akdemir Ü. Ö., Yildiz R., Akyol G., Demirci U., Buyukberber S., Tezel E., et al.  
JOURNAL OF CLINICAL PATHOLOGY, vol.62, no.11, pp.1053-1055, 2009 (SCI-Expanded)
- LXXXVII. **Primary pure small cell carcinoma of the urinary bladder that responded to carboplatin plus etoposide: a case report and review of the literature**  
Kaya A. O., Coskun U., Yildiz R., Gonul I. I., Karagulle K., Yaman E., Ozturk B.  
JOURNAL OF BUON, vol.14, no.4, pp.703-706, 2009 (SCI-Expanded)
- LXXXVIII. **Gemcitabine Combined With Uracil-Tegafur in Patients With Advanced Pancreatic Cancer**  
Coskun U., Alkis N., Celenkoglu G., Buyukberber S., ÖZKAN M., Camci C., ÜNER A., ER Ö., Aslan U. Y., Sevinc A., et al.  
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, vol.101, no.8, pp.761-764, 2009 (SCI-Expanded)
- LXXXIX. **Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells**  
Donkor M. K., Lahue E., Hoke T. A., Shafer L. R., Coskun U., Solheim J. C., Gulen D., Bishay J., Talmadge J. E.  
International Immunopharmacology, vol.9, no.7-8, pp.937-948, 2009 (SCI-Expanded)
- XC. **Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors**

- Ozturk B., Coskun U., Sancak B., Yaman E., Buyukberber S., Benekli M.  
INTERNATIONAL IMMUNOPHARMACOLOGY, vol.9, no.5, pp.645-648, 2009 (SCI-Expanded)
- XCI. **Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma**  
Yaman E., Coskun U., Ozturk B., Buyukberber S., Kaya A. O., Coskun Ö., Buyukberber N., YILDIZ R., Benekli M.  
JOURNAL OF CLINICAL NEUROSCIENCE, vol.16, no.4, pp.591-592, 2009 (SCI-Expanded)
- XCII. **Metastatic fibroblastic reticulum cell sarcoma of the liver: pathological and PET-CT evaluation**  
Yaman E., IŞIK GÖNÜL İ., Buyukberber S., Ozturk B., AKYÜREK N., Coskun U., Kaya A. O., YILDIZ R., ŞARE M., Kitapci M.  
PATHOLOGY, vol.41, no.3, pp.289-292, 2009 (SCI-Expanded)
- XCIII. **Vinorelbine in Combination with Carboplatin followed by Single-agent Consolidation Therapy for Unresectable Localized or Metastatic Non-small-cell Lung Carcinomas**  
Alici S., Coskun U., Alkis N., Sevinc A., Dane F., Gumus M., ÖZKAN M., Kaya A. O., Celenkoglu G., Buyukberber S., et al.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.10, no.6, pp.1051-1055, 2009 (SCI-Expanded)
- XCIV. **Serum Granulocyte Macrophage-Colony Stimulating Factor: a Tumor Marker in Colorectal Carcinoma?**  
Demirci U., Coskun U., Sancak B., Ozturk B., Bahar B., Benekli M., Buyukberber S.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.10, no.6, pp.1021-1024, 2009 (SCI-Expanded)
- XCV. **UFT plus Oral Folinic Acid with Alternating Oral and Intravenous Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes**  
Coskun U., Kaya A. O., Alkis N., Buyukberber S., Alici S., Celenkoglu G., Uncu D., ÖZKAN M., Sevinc A., Benekli M.  
ONKOLOGIE, vol.32, no.10, pp.562-566, 2009 (SCI-Expanded)
- XCVI. **Non-Gestational Uterine Choriocarcinoma in a Postmenopausal Woman**  
YILDIZ R., Benekli M., AKYÜREK N., Coskun U., Kaya A. O., Ozturk B., Yaman E., Buyukberber S.  
ONKOLOGIE, vol.32, no.7, pp.417-419, 2009 (SCI-Expanded)
- XCVII. **Gemcitabine-Induced Acute Coronary Syndrome: A Case Report**  
Ozturk B., TAÇOY G., Coskun U., Yaman E., Sahin G., Buyukberber S., YILDIZ R., Kaya A. O., TOPAL S., Ozdemir M., et al.  
MEDICAL PRINCIPLES AND PRACTICE, vol.18, no.1, pp.76-80, 2009 (SCI-Expanded)
- XCVIII. **Increased Serum Granulocyte Colony Stimulating Factor in Turkish Hepatocellular Carcinoma Patients**  
Kaya A. O., Coskun U., Sancak B., Buyukberber S., YILDIZ R., GÜLBAHAR Ö., Benekli M., Ozenirler S.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.10, no.3, pp.403-405, 2009 (SCI-Expanded)
- XCIX. **Serum neopterin levels in patients with breast cancer**  
Yildirim Y., GÜNEL N., Coskun U., PAŞAOĞLU H., Aslan S., Cetin A.  
MEDICAL ONCOLOGY, vol.25, no.4, pp.403-407, 2008 (SCI-Expanded)
- C. **Histiocytic sarcoma: PET-CT evaluation of a rare entity**  
Yaman E., Ozturk B., ERDEM O. A., Gokcorna N., Coskun U., Uluoglu O., Benekli M.  
ANNALS OF NUCLEAR MEDICINE, vol.22, no.8, pp.715-717, 2008 (SCI-Expanded)
- CI. **Intrasellar plasmacytoma: an unusual presentation of multiple myeloma**  
Yaman E., Benekli M., Coskun U., Sezer K., Ozturk B., Kaya A. O., Yildiz R., Uluoglu O., Buyukberber S.  
ACTA NEUROCHIRURGICA, vol.150, no.9, pp.921-924, 2008 (SCI-Expanded)
- CII. **Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer**  
Acar A., Onan A., Coskun U., ÜNER A., BAĞRIAÇIK E. Ü., Atalay F., Unsal D. K., Guner H.  
MEDICAL ONCOLOGY, vol.25, no.3, pp.279-283, 2008 (SCI-Expanded)
- CIII. **Carboplatin and oral cyclophosphamide combination after temozolomide failure in malignant gliomas**  
Yaman E., Buyukberber S., ÜNER A., Coskun U., Yamac D., Ozturk B., Kaya A. O., YILDIZ R., Benekli M.  
TUMORI J, vol.94, no.5, pp.674-680, 2008 (SCI-Expanded)
- CIV. **The results of three different treatment modalities in patients with locally advanced nasopharyngeal carcinoma**

- Ozturk B., Buyukberber S., Akmansu M., Coskun U., Yamac D., Uner A., Yaman E., Yildiz R., Kaya A. O., Bora H., et al.  
MEDICAL ONCOLOGY, vol.25, no.3, pp.269-273, 2008 (SCI-Expanded)
- CV.** **WITHDRAWN: Significance of serum vascular endothelial growth factor, insulin-like growth factor-I levels and nitric oxide activity in breast cancer patients.**  
Coşkun U., Günel N., Sancak B., Günel U., Onuk E., Bayram O., Yılmaz E., Candan S., Ozkan S.  
Breast (Edinburgh, Scotland), 2008 (SCI-Expanded)
- CVI.** **Serum big endothelin-1 levels in female patients with breast cancer**  
Yıldırım Y., GÜNEL N., Coskun U., Sancak B., BUKAN N., Aslan S., Cetin A.  
INTERNATIONAL IMMUNOPHARMACOLOGY, vol.8, no.8, pp.1119-1123, 2008 (SCI-Expanded)
- CVII.** **Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer**  
Yamac D., Ozturk B., Coskun U., Tekin E., Sancak B., YILDIZ R., Atalay C.  
ADVANCES IN THERAPY, vol.25, no.8, pp.801-809, 2008 (SCI-Expanded)
- CVIII.** **Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane plus platinum regimens**  
Coskun U., Kaya A. O., Buyukberber S., Benekli M., ÜNER A., Dikilitas M., Ozturk B., YILDIZ R., ÖZKAN S., Yaman E., et al.  
MEDICAL ONCOLOGY, vol.25, no.2, pp.133-136, 2008 (SCI-Expanded)
- CIX.** **Disseminated extranodal NK/T-cell lymphoma, nasal type, with multiple subcutaneous nodules - Utility of 18F-FDG PET in staging**  
Berk V., YILDIZ R., AKDEMİR Ü. Ö., AKYÜREK N., KARABACAK N., Coskun U., Benekli M.  
CLINICAL NUCLEAR MEDICINE, vol.33, no.5, pp.365-366, 2008 (SCI-Expanded)
- CX.** **Reply to the article "Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18 : 1165-1171)**  
Yaman E., Benekli M., Coskun U., Ozturk B., Kaya A. O., Yildiz R., Buyukberber S.  
ANNALS OF ONCOLOGY, vol.19, no.2, pp.397-398, 2008 (SCI-Expanded)
- CXI.** **Acute erythema and edematous skin reaction and ectropion following docetaxel in a patient with non-small cell lung cancer**  
Kaya A. O., Buyukberber S., Coskun U., YILDIZ R., Ozturk B., Yaman E., ADİŞEN E., Gureli M., Benekli M.  
CUTANEOUS AND OCULAR TOXICOLOGY, vol.27, no.4, pp.327-331, 2008 (SCI-Expanded)
- CXII.** **Synchronize primary breast osteosarcoma and contralateral benign cystosarcoma phylloides: Radiologic and pathologic imaging**  
ÜNER A., Ozturk B., Benekli M., Coskun U., Kocak S., Kaya A. O., Unsal D., Erekul S., Yaman E., YILDIZ R., et al.  
BREAST JOURNAL, vol.14, no.1, pp.109-110, 2008 (SCI-Expanded)
- CXIII.** **Coexistence of Gastrointestinal Stromal Tumor (GIST) of the Rectum and Adenocarcinoma of the Prostate in a Patient with Familial GIST**  
Yaman E., Coskun U., Benekli M., Sozen S., Yamac D., Buyukberber S., Ozturk B., Kaya A. O., YILDIZ R., TEZEL E.  
ONKOLOGIE, vol.31, no.12, pp.697-699, 2008 (SCI-Expanded)
- CXIV.** **Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients**  
Coskun U., Buyukberber S., Yaman E., Uner A., Er O., Ozkan M., Dikilitas M., Oguz M., Yildiz R., Yamac D., et al.  
NEOPLASMA, vol.55, no.1, pp.65-70, 2008 (SCI-Expanded)
- CXV.** **Whole Body 18F-FDG PET/CT Imaging in the Detection of Primary Tumours in Patients with a Metastatic Carcinoma of Unknown Origin**  
Kaya A. O., Coskun U., ÜNLÜ M., AKDEMİR Ü. Ö., ÖZDEMİR N., Zengin N., Benekli M., YILDIZ R., Yaman E., Ozturk B., et al.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.9, no.4, pp.683-686, 2008 (SCI-Expanded)
- CXVI.** **Temozolomide in newly diagnosed malignant gliomas: Administered concomitantly with radiotherapy, and thereafter as consolidation treatment**  
Yaman E., Buyukberber S., ÜNER A., Coskun U., AKMANSU M., Benekli M., Yamac D., Ozturk B., Kaya A. O., YILDIZ R., et al.

- ONKOLOGIE, vol.31, no.6, pp.309-313, 2008 (SCI-Expanded)
- CXVII. **Cyclooxygenase-2 expression and its association with angiogenesis, Helicobacter pylori, and clinicopathologic characteristics of gastric carcinoma**  
Yamac D., Ayyildiz T., Coskun U., AKYÜREK N., DURSUN A., Seckin S., Koybasioglu F.  
PATHOLOGY RESEARCH AND PRACTICE, vol.204, no.8, pp.527-536, 2008 (SCI-Expanded)
- CXVIII. **F-18FDG uptake due to acinetobacter infection causing misinterpretation of treatment response in a lymphoma patient**  
Yildiz R., Coskun U., Kapucu O., Kaya A. O., Akdemir Ü. Ö., Benekli M., Buyukberber S.  
CLINICAL NUCLEAR MEDICINE, vol.32, no.6, pp.471-473, 2007 (SCI-Expanded)
- CXIX. **Digital ischemic changes after gemcitabine therapy in a patient with metastatic non-small-cell lung cancer**  
Yildiz R., Coskum U., Kaya A. C., Ozturk B., Yaman E.  
ANNALS OF PHARMACOTHERAPY, vol.41, no.5, pp.901-902, 2007 (SCI-Expanded)
- CXX. **Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer**  
Yaman E., Uner A., Er O., Coskun U., Buyukberber S., Dikilitas M., Polat M., Yamac D., Kaya A. O., Yildiz R., et al.  
MEDICAL ONCOLOGY, vol.24, no.4, pp.431-435, 2007 (SCI-Expanded)
- CXXI. **Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response?**  
Coskun U., Yamac D., Gulbahar Ö., Sancak B., Karaman N., Ozkan S.  
NEOPLASMA, vol.54, no.4, pp.348-352, 2007 (SCI-Expanded)
- CXXII. **Solitary iris metastasis from breast cancer with dramatic course: case report**  
Ozturk B., Buyukberber S., Coskun U., Yaman E., Yildiz R., Kaya A. O., Oner Y., Benekli M.  
MEDICAL ONCOLOGY, vol.24, no.4, pp.463-465, 2007 (SCI-Expanded)
- CXXIII. **Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes**  
Benekli M., YILDIZ R., ÜNER A., Er O., Yamac D., Alkis N., Coskun U., Camci C., Buyukberber S.  
ONCOLOGY, vol.72, pp.308-313, 2007 (SCI-Expanded)
- CXXIV. **Serum P-selectin, soluble vascular cell adhesion molecule-I (s-VCAM-I) and soluble intercellular adhesion molecule-I (s-ICAM-I) levels in bladder carcinoma patients with different stages**  
Coskun U., Sancak B., Sen İ., Bukan N., Tufan M., Gulbahar Ö., Sozen S.  
INTERNATIONAL IMMUNOPHARMACOLOGY, vol.6, no.4, pp.672-677, 2006 (SCI-Expanded)
- CXXV. **Interdigitating dendritic cell tumor with breast and cervical lymph-node involvement: a case report and review of the literature**  
Uluoglu O., Akyurek N., Uner A., Coskun U., Ozdemir A., Gokcorna N.  
VIRCHOWS ARCHIV, vol.446, no.5, pp.546-554, 2005 (SCI-Expanded)
- CXXVI. **The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma**  
ERDEM O. A., Dursun A., Coskun U., Gunel N.  
TUMORI J, vol.91, no.1, pp.46-52, 2005 (SCI-Expanded)
- CXXVII. **Prognostic importance of COX-2 expression in patients with colorectal cancer**  
Yamac D., Celenkoglu G., Coskun U., Akyurek N., Akcali Z., Dursun A., Koybasioglu F.  
PATHOLOGY RESEARCH AND PRACTICE, vol.201, no.7, pp.497-502, 2005 (SCI-Expanded)
- CXXVIII. **Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients**  
Coskun U., Gunel N., Sancak B., Onuk E., Bayram M., Cihan A.  
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol.137, no.3, pp.546-551, 2004 (SCI-Expanded)
- CXXIX. **No association between serum levels of insulin-like growth factor-I, vascular endothelial growth factor, prolactin and clinicopathological characteristics of breast carcinoma after surgery.**  
Sancak B., Coskun U., Gunel N., Onuk E., Cihan A., Karamercan A., Yildirim Y., Ozkan S.  
Internal medicine journal, vol.34, no.6, pp.310-5, 2004 (SCI-Expanded)

- CXXX. **Polymyositis and hepatitis concurrent with breast cancer**  
Yamac D., Gunel N., Goker B., Coskun U., ERDEM O. A., Akyol G., Ozenirler S.  
MEDICAL PRINCIPLES AND PRACTICE, vol.13, no.3, pp.171-175, 2004 (SCI-Expanded)
- CXXXI. **Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions**  
Coskun U., Bukan N., Sancak B., Gunel N., Ozenirler S., Unal A., ATAK YÜCEL A.  
NEOPLASMA, vol.51, no.3, pp.209-213, 2004 (SCI-Expanded)
- CXXXII. **Serum levels of interleukin-18 and nitrite+nitrate in renal cell carcinoma patients with different tumor stage and grade.**  
Sözen S., Coskun U., Sancak B., Bukan N., Günel N., Tunc L., Bozkirli I.  
Neoplasma, vol.51, no.1, pp.25-9, 2004 (SCI-Expanded)
- CXXXIII. **Prognostic value of serum IL-18 and nitric oxide activity in breast cancer patients at operable stage**  
Gunel N., Coskun U., Sancak B., Hasdemir O., Sare M., Bayram O., Celenkoglu G., Ozkan S.  
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.26, no.4, pp.416-421, 2003 (SCI-Expanded)
- CXXXIV. **Serum interleukin-18 and nitric oxide activity in bladder carcinoma**  
Bukan N., Sozen S., Coskun U., Sancak B., Gunel N., Bozkirli I., Senocak C.  
EUROPEAN CYTOKINE NETWORK, vol.14, no.3, pp.163-167, 2003 (SCI-Expanded)
- CXXXV. **Significance of serum vascular endothelial growth factor, insulin-like growth factor-I levels and nitric oxide activity in breast cancer patients**  
Coskun U., Gunel N., Sancak B., Gunel U., Onuk E., Bayram O., Yilmaz E., Candan S., Ozkan S.  
BREAST, vol.12, no.2, pp.104-110, 2003 (SCI-Expanded)
- CXXXVI. **Gingival metastasis of malignant mesenchymal tumour in the thigh**  
Gunel N., Coskun U., Simsek B., Seckin S., Cengiz O., Gunel U., Gultekin S. E.  
BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, vol.41, no.1, pp.59-61, 2003 (SCI-Expanded)
- CXXXVII. **Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.**  
Coskun U., Gunel N., Onuk E., Yilmaz E., Bayram O., Yamac D., Cihan A., Ucan B., Yildirim Y., Celenkoglu G., et al.  
Neoplasma, vol.50, no.3, pp.210-6, 2003 (SCI-Expanded)
- CXXXVIII. **Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer.**  
Coskun U., Gunel N., Toruner F. S., Sancak B., Onuk E., Bayram O., Cengiz O., Yilmaz E., Elbeg S., Ozkan S.  
Neoplasma, vol.50, no.1, pp.41-6, 2003 (SCI-Expanded)
- CXXXIX. **Serum leptin levels are associated with tamoxifen-induced hepatic steatosis.**  
Gunel N., Coskun U., Toruner F. S., Sancak B., Yilmaz E., Cengiz O., Elbeg S., Uner A., Ozkan S.  
Current medical research and opinion, vol.19, no.1, pp.47-50, 2003 (SCI-Expanded)
- CXL. **Primary mediastinal yolk sac tumor in a 66-year-old woman**  
Coskun U., Gunel N., Yildirim Y., Memis L., Boyacioglu Z.  
MEDICAL PRINCIPLES AND PRACTICE, vol.11, no.4, pp.218-220, 2002 (SCI-Expanded)
- CXLI. **Primary high grade malignant lymphoma of bladder**  
Coskun U., Gunel N., EROĞLU A., Biri H., Poyraz A., Gurocak S., Bali M.  
UROLOGIC ONCOLOGY, vol.7, no.5, pp.181-183, 2002 (SCI-Expanded)
- CXLII. **Clinical importance of serum interleukin-18 and nitric oxide activities in breast carcinoma patients**  
Gunel N., Coskun U., Sancak B., Gunel U., Hasdemir O., Bozkurt S.  
CANCER, vol.95, no.3, pp.663-667, 2002 (SCI-Expanded)
- CXLIII. **A case of Sweet's syndrome developed after the treatment of herpes simplex infection in a metastatic breast cancer patient**  
Coskun U., Gunel N., Senol E., Ilter N., Dursun A., Tuzun D.  
JOURNAL OF CUTANEOUS PATHOLOGY, vol.29, no.5, pp.301-304, 2002 (SCI-Expanded)
- CXLIV. **Tamoxifen therapy and hepatic steatosis.**  
Coskun U., Toruner F. S., Gunel N.  
Neoplasma, vol.49, no.1, pp.61-4, 2002 (SCI-Expanded)

- CXLV. **Prognostic importance of tumor angiogenesis in breast carcinoma with adjuvant chemotherapy**  
Gunel N., Akcali Z., Coskun U., Akyol G., Yamac D., Yenidunya S.  
PATHOLOGY RESEARCH AND PRACTICE, vol.198, no.1, pp.7-12, 2002 (SCI-Expanded)
- CXLVI. **Effect of cisplatin on skin metastasis in breast cancer patients**  
Coskun U., Gunel N., Yamac D., Altinova A.  
ONKOLOGIE, vol.24, no.6, pp.576-579, 2001 (SCI-Expanded)
- CXLVII. **Serum and ascitic fluid nitrate levels in patients with cirrhosis**  
Coskun U., Ozenirler S., Sancak B., Bukan N.  
CLINICA CHIMICA ACTA, vol.306, pp.127-132, 2001 (SCI-Expanded)
- CXLVIII. **Cisplatin plus vinorelbine as a salvage regimen in refractory breast cancer**  
Gunel N., Akcali Z., Yamac D., Onuk E., Yilmaz E., Bayram O., Tekin E., Coskun U.  
TUMORI, vol.86, no.4, pp.283-285, 2000 (SCI-Expanded)

### Articles Published in Other Journals

- I. **Isolated mucinous adrenal metastasis in a breast cancer patient**  
Demirci U., BÜYÜKBERBER S., Cakir T., POYRAZ A., Baykara M., Karakus E., Tufan G., BENEKLİ M., COŞKUN U.  
Journal of Oncology Pharmacy Practice, vol.17, no.4, pp.444-447, 2011 (Scopus)
- II. **Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus**  
ÇETİN B. E., COŞKUN U., YILDIZ R., BÜYÜKBERBER S., Baykara M., BENEKLİ M.  
Journal of Oncology Pharmacy Practice, vol.17, no.3, pp.274-278, 2011 (Scopus)
- III. **Acne rosacea associated imatinib mesylate in a gastrointestinal stromal tumor patient**  
Demirci U., COŞKUN U., ERDEM Ö., Ozturk B., YILMAZ İ., BENEKLİ M., BÜYÜKBERBER S.  
Journal of Oncology Pharmacy Practice, vol.17, no.3, pp.285-287, 2011 (Scopus)
- IV. **Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens**  
Yildiz R., Kalender M. E., Dane F., Sevinc A., Gumus M., Camci C., Alici S., Kaya A. O., Yaman E., Ozturk B., et al.  
Journal of Oncology Pharmacy Practice, vol.16, no.3, pp.173-178, 2010 (Scopus)
- V. **Four different malignancies in one patient: a case report.**  
Demirci U., Coşkun U., Göcün P. U., Gurlek B., Saka B., Oztürk B., Benekli M., Büyükerberber S.  
Cases journal, vol.3, pp.53, 2010 (Peer-Reviewed Journal)
- VI. **Synchronous testicular liposarcoma and prostate adenocarcinoma: A case report**  
Demirci U., BÜYÜKBERBER S., ÇAKIR A., Ozturk B., AKYÜREK N., Unver B., Baykara M., BENEKLİ M., COŞKUN U.  
Cases Journal, vol.3, no.1, 2010 (Scopus)
- VII. **Serum and ascitic fluid superoxide dismutase and malondialdehyde levels in patients with cirrhosis**  
Ozenirler S., Sancak B., COŞKUN U.  
Biomarker Insights, vol.2008, no.3, pp.141-145, 2008 (Scopus)